Amphetamine Addiction
Conditions
Keywords
Amphetamine-type stimulants, prefrontal-striatal circuits, rTMS, Glutamate/GABA, motivational and cognitive intervention
Brief summary
The repetitive transcranial magnetic stimulation (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.
Detailed description
The Glutamate and GABA deficits in prefrontal cortex play a vital role in ATS addiction and relapse, and proposed repetitive transcranial magnetic stimulation (rTMS) as a novel interventions. Focused on evaluating Glutamate/GABA functions in prefrontal cortex and functional connectivity with deep brain regions, neuropsychological tests, biochemical tests, magnetic resonance spectroscopy (MRS) and functional MRI will be used to investigate the neurobiological mechanism of ATS addiction and relapse. These methods will also be used to evaluate the efficacy of the novel intervention and investigate the mechanisms. The study will be very helpful to develop novel interventions in clinical practice and decrease ATS-related harm for both the patients and their families.
Interventions
RADIATIONrepetitive transcranial magnetic stimulation (rTMS)
Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
Sponsors
Yunnan Institute For Drug Abuse
Shanghai Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders * Dextromanual
Exclusion criteria
* Have a disease that affect cognitive function such as history of head injury, cerebrovascular disease, epilepsy, etc * Have cognitive-promoting drugs in the last 6 months * Other substance abuse or dependence in recent five years (except nicotine) * Mental impairment, Intelligence Quotient (IQ) \< 70 * Mental disorders * Physical disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) at 1 month | Baseline and 1 month | evaluate all participants' craving for ATS by Visual Analog Scales (VAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who relapse | 1 month | Follow up with patients after discharge, evaluate number of participants who relapse |
| Depression status assessed by Patient Health Questionnaire-9(PHQ-9) | 1 month | evaluate all participants' depression status by Patient Health Questionnaire-9(PHQ-9) |
| Anxiety status assessed by Generalized Anxiety Disorder Screener (GAD-7) | 1 month | evaluate all participants' anxiety status by Generalized Anxiety Disorder Screener (GAD-7) |
| Cognitive function assessed by Cogstate Battery | 1 month | evaluate all participants' cognition by Cogstate Battery Chinese version |
| Functional connectivity assessed by MRI | 1 month | evaluate all participants' functional connectivity in the brain by MRI |
Countries
China
Outcome results
None listed